Iterum Therapeutics plc (NASDAQ:ITRM) Sees Significant Increase in Short Interest

Iterum Therapeutics plc (NASDAQ:ITRM) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 2,530,000 shares, an increase of 1,082.8% from the October 15th total of 213,900 shares. Based on an average daily volume of 2,330,000 shares, the days-to-cover ratio is presently 1.1 days. Approximately 11.5% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Iterum Therapeutics in a research report on Tuesday, September 10th.

Iterum Therapeutics Stock Up 6.5 %

Shares of ITRM stock traded up $0.09 during trading on Tuesday, hitting $1.48. The company had a trading volume of 1,411,691 shares, compared to its average volume of 953,775. The stock’s 50-day moving average is $1.13 and its two-hundred day moving average is $1.25. The stock has a market capitalization of $33.61 million, a price-to-earnings ratio of -0.70 and a beta of 2.25. Iterum Therapeutics has a 52 week low of $0.71 and a 52 week high of $2.50.

Iterum Therapeutics (NASDAQ:ITRM) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.22. On average, research analysts predict that Iterum Therapeutics will post -1.19 EPS for the current fiscal year.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.